ISD vs REPL Comparison

PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.